ClinicalTrials.gg
CompletedNCT02658214Updated Aug 20, 2020

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

A Phase 1 interventional study of paclitaxel + carboplatin and carboplatin + etoposide in Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck and Stomach Neoplasms, sponsored by AstraZeneca. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing durvalumab in Small Cell Lung Carcinoma — 10 open to participants now, 19 under way, 3 of them phase 3. durvalumab · Small Cell Lung Carcinoma.

Enrollment
28th of 36
32 · median 50
Started
2016
with 3 others
Phase 1
6 of 36
1 open now
Registered
1st of 36
by date
Lead sponsor
12 of 36
AstraZeneca

Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, this one is the 28th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 1, and was the 1st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

10 of the 36 studies testing durvalumab in Small Cell Lung Carcinoma are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing durvalumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.

Read the detailed description

7 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab.

This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), small cell lung carcinoma (SCLC), and gastric/gastro-esophageal junction (GEJ) cancer, pancreatic ductal adenocarcinoma (PDAC) and esophageal squamous cell carcinoma (ESCC).

03

Conditions studied

  • Small Cell Lung Carcinoma
  • Carcinoma, Squamous Cell of Head and Neck
  • Stomach Neoplasms
  • Triple Negative Breast Neoplasms
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Esophagogastric Junction Neoplasms
  • Carcinoma, Pancreatic Ductal
  • Esophageal Squamous Cell Carcinoma

Keywords

  • durvalumab, tremelimumab, metastatic, solid tumors, immuno-oncology, first-line chemotherapy, esophageal, pancreatic
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years
  2. Written
  3. Patients with or cytologically documented chemotherapy-naïve locally advanced unresectable or ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC, gastric cancer/GEJ, PDAC and ESCC.
  4. performance status of 0 or 1
  5. Patients must be considered suitable candidates for, and able to receive, chemotherapy for metastatic disease
  6. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline
  7. No prior exposure to immune-mediated therapy
  8. Adequate organ and marrow function as defined below

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any anticancer therapy within 28 days or 5 halflives, whichever is longer, prior to the first dose of study treatment
  2. or spinal cord compression unless asymptomatic or treated and stable off and anti-convulsants for at least 1 month prior to study treatment
  3. Any unresolved Grade ≥2 toxicity from previous anticancer therapy
  4. Active or prior documented or inflammatory disorders
  5. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study drugs, or compromise the ability of the patient to give written
  6. Mean corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms 20. Active tuberculosis
  7. Active infection including tuberculosis, , , or (HIV)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1

    ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)

    Drug: paclitaxel + carboplatin · Biological: durvalumab · Biological: tremelimumab

  • Experimental
    Cohort 2

    Small-cell lung cancer (SCLC)

    Drug: carboplatin + etoposide · Biological: durvalumab · Biological: tremelimumab

  • Experimental
    Cohort 3

    Triple-negative breast cancer (TNBC)

    Drug: gemcitabine + carboplatin · Biological: durvalumab · Biological: tremelimumab

  • Experimental
    Cohort 4

    Triple-negative breast cancer (TNBC)

    Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin · Biological: durvalumab · Biological: tremelimumab

  • Experimental
    Cohort 5

    Gastric/gastro-esophageal junction (GEJ)

    Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid) · Biological: durvalumab · Biological: tremelimumab

  • Experimental
    Cohort 6

    Pancreatic ductal adenocarcinoma (PDAC)

    Biological: durvalumab · Biological: tremelimumab · Drug: nab-paclitaxel (paclitaxel-albumin) + gemcitabine

  • Experimental
    Cohort 7

    Esophageal squamous cell carcinoma (ESCC)

    Biological: durvalumab · Biological: tremelimumab · Drug: cisplatin + 5-fluorouracil (5FU)

Interventions

  • Drugpaclitaxel + carboplatin

    Drug pages: Paclitaxel · Carboplatin

    IV infusion

    Also known as: Platinum based Standard of Care Chemotherapy

  • Drugcarboplatin + etoposide

    Drug pages: Carboplatin · Etoposide

    IV infusion

    Also known as: Platinum based Standard of Care Chemotherapy

  • Druggemcitabine + carboplatin

    Drug pages: Gemcitabine · Carboplatin

    IV infusion

    Also known as: Platinum based Standard of Care Chemotherapy

  • Drugnab-paclitaxel (paclitaxel-albumin) + carboplatin

    Drug page: Albumin-Bound Paclitaxel

    IV infusion

    Also known as: Platinum based Standard of Care Chemotherapy

  • Drugoxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)

    Drug pages: Oxaliplatin · Fluorouracil · Leucovorin

    IV infusion and bolus administration

    Also known as: Platinum based Standard of Care Chemotherapy

  • Biologicaldurvalumab

    IV infusion

    Also known as: MEDI4736

  • Biologicaltremelimumab

    IV infusion

  • Drugnab-paclitaxel (paclitaxel-albumin) + gemcitabine

    Drug page: Albumin-Bound Paclitaxel

    IV infusion

    Also known as: Standard of Care Chemotherapy

  • Drugcisplatin + 5-fluorouracil (5FU)

    Drug pages: Cisplatin · Fluorouracil

    IV infusion

    Also known as: Platinum based Standard of Care Chemotherapy

06

What researchers measure

Primary outcomes

  1. Laboratory findings (including: clinical chemistry, hematology, and urinalysis)

    To assess the safety and tolerability profile of first-line chemotherapy in combination with durvalumab + tremelimumab

    Time frame: Throughout the study, approximately three years

  2. Incidence of Adverse Events

    To assess incidence of Adverse Events for the safety and tolerability profile of first-line chemotherapy in combination with durvalumab and tremelimumab

    Time frame: Throughout the study, approximately three years

  3. Tumor assessment based on RECIST 1.1 (for cohort 6 only)

    To estimate the objective response rate (ORR) of durvalumab + tremelimumab + chemotherapy (for cohort 6 only)

    Time frame: Throughout the study, approximately three years (for cohort 6 only)

07

Study locations

6 sites
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Nov 2019, 42 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 42 months is close to that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2016
First posted
Jan 18, 2016
StartActual
Apr 28, 2016
Primary completionActual
Nov 14, 2019
CompletionActual
Nov 14, 2019
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02658214
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 18, 2016
Start date
Apr 28, 2016
Primary completion
Nov 14, 2019
Completion
Nov 14, 2019
Last update
Aug 20, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion